Peter Lio, MD, of Medical Dermatology Associates of Chicago in Chicago, Illinois, discusses recent innovations in atopic dermatitis therapies with regard to JAK inhibitors. Dr. Lio discusses several new drugs in this class, including topical ruxolitinib, oral abrocitinib, and oral upadacitinib, and provides important guidance for practitioners treating their patients with these new therapies.

Dr. Guttman-Yassky discusses a post-hoc analysis that evaluated the efficacy of upadacitinib after 140 weeks in patients with atopic dermatitis. Reference: Butler D, et al....
PLAY